28/03/2012 | 07:30 CEST | Group Announcements
Staefa (Switzerland), 28.03.2012 – Sonova introduces new products from Phonak, Unitron and Advanced Bionics at the AudiologyNOW! conference in Boston, USA.
Innovation leadership continues
Phonak
Phonak presents the new generation Lyric, a 100% invisible and extended wear hearing aid. In developing a new generation of Lyric devices, Phonak reduced the size of the hearing aid and thereby increased the anatomical fit rate by 50%. Lyric can be worn for up to four months without removing the device or changing batteries. Positioned close to the eardrum, Lyric makes use of the anatomical function of the pinna and offers natural sound quality and excellent wearing comfort.
Phonak is introducing its new performance level, Essential, based on the Spice+ technology. The new Essential products provide state-of-the-art Spice+ features at a very competitive price. Essential includes a new product family named Phonak Dalia as well as an entry-level model of the award-winning Audéo S SMART I and Naída S I. With this new performance level, Phonak meets the needs of end-users who are seeking value for money products without compromising on latest technology and state-of-the-art features.
Unitron
Unitron announces the introduction of the new premium hearing instruments for its Quantum™ and Moxi™ product families. Built on Era™, Unitron’s latest generation platform, Quantum Pro and Moxi Pro deliver innovative binaural spatial processing and SpeechZone™ to enrich clients’ hearing experience and speech understanding, even in the most challenging listening environments. Unitron also presented the uDirect™ 2 and uTV™ 2 accessories.
The Quantum family of custom products was expanded to include a tiny custom micro CIC. It is the tiniest Quantum ever delivered, yet continues to provide high-fidelity natural sound. It is a great hearing instrument for a first time wearer, offering a fully automatic, natural listening experience and fit right from the start.
Advanced Bionics
Advanced Bionics (AB) announced on March 19, 2012 the FDA approval of ClearVoice™ in the United States. ClearVoice™ is already approved for use in Europe, Asia and Canada. Built on AB’s proprietary HiRes Fidelity 120™* technology for high-performance hearing, ClearVoice™ has been designed to automatically analyze and adapt to each listening situation encountered throughout the day of a cochlear implant wearer, separating the distracting noises from speech so that communication can be a truly effortless experience. ClearVoice™ is the first and only speech enhancement technology available in the cochlear implant market, further solidifying AB’s position as the industry’s innovation leader. (*Not yet approved for pediatric use in the United States.)
For further information about the products, please find below the trade press releases of the respective brands.
– End –